中国实用内科杂志 ›› 2013, Vol. 33 ›› Issue (1): 38-41.
• 指南论坛 • 上一篇 下一篇
肖卫国
出版日期:
发布日期:
XIAO Wei-guo
Online:
Published:
摘要:
摘要:与美国风湿病协会(ACR)2008年治疗类风湿关节炎(RA)推荐意见相比,ACR 2012新的RA治疗推荐在治疗药物的选择与转换、高危人群生物制剂的选择、结核病的筛查及疫苗接种等方面提出了更详尽的建议。文章就该推荐的更新要点进行解读,以期对中国RA的临床治疗提供有意义的指导。
关键词: 类风湿关节炎, 改善病情抗风湿药, 生物制剂, 肿瘤坏死因子-&alpha
Abstract:
Abstract:The 2012 American College of Rheumatology (ACR) Recommendations for Treatment of Rheumatoid Arthritis has updated delineation in the selection and switching of medications,optimization of biologic agents in highrisk population,screening of tuberculosis and vaccination,as compared with the 2008 recommendations.In this review,the major updates were outlined to steer clinical management of rheumatoid arthritis in China.
Key words: rheumatoid arthritis, diseasemodifying anti-rheumatic drug, biologic agents, tumor necrosis factor-&alpha
中图分类号:
R593.2
肖卫国. 美国风湿病协会2012年类风湿关节炎治疗推荐意见解读[J]. 中国实用内科杂志, 2013, 33(1): 38-41.
XIAO Wei-guo . The 2012 American College of Rheumatology Recommendations for treatment of rheumatoid arthritis [J]. , 2013, 33(1): 38-41.
0 / 推荐
导出引用管理器 EndNote|Ris|BibTeX
链接本文: http://www.zgsyz.com/zgsynk/CN/
http://www.zgsyz.com/zgsynk/CN/Y2013/V33/I1/38